These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27181545)

  • 61. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.
    Tsubokura Y; Satake A; Hotta M; Yoshimura H; Fujita S; Azuma Y; Nakanishi T; Nakaya A; Ito T; Ishii K; Nomura S
    Int J Hematol; 2016 Dec; 104(6):744-748. PubMed ID: 27573760
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research.
    Tsukasaki K; Tobinai K
    Clin Cancer Res; 2014 Oct; 20(20):5217-25. PubMed ID: 25320371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
    Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Haploidentical transplantation using post-transplant high-dose cyclophosphamide for adult T-cell lymphoma after mogamulizumab treatment].
    Kusakabe M; Kurita N; Nishikii H; Sato R; Yoshida C; Yokoyama Y; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Rinsho Ketsueki; 2017; 58(5):449-454. PubMed ID: 28592758
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
    Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
    Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
    [TBL] [Abstract][Full Text] [Related]  

  • 68. No effect of humanized CCR monoclonal antibody (mogamulizumab) on treatment-resistant adult T cell leukemia with meningeal infiltration.
    Tsutsumi Y; Shimono J; Miyashita N; Teshima T
    Leuk Lymphoma; 2014 Feb; 55(2):457-9. PubMed ID: 23697876
    [No Abstract]   [Full Text] [Related]  

  • 69. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
    Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
    Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
    [No Abstract]   [Full Text] [Related]  

  • 70. Successful treatment strategy in corporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report.
    Nakata K; Fuji S; Koike M; Tada Y; Masaie H; Yoshida H; Watanabe E; Kobayashi S; Tojo A; Uchimaru K; Ishikawa J
    Blood Cell Ther; 2020 Feb; 3(1):6-10. PubMed ID: 37465376
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
    Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Blood Adv; 2020 May; 4(10):2180-2191. PubMed ID: 32433748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Progress in the management of ATL].
    Ishitsuka K
    Rinsho Ketsueki; 2017; 58(6):676-682. PubMed ID: 28680001
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment.
    Tanaka H; Aoki H; Sugita Y; Shimizu R; Kiko K; Mochida H; Suzuki Y
    Intern Med; 2017 Oct; 56(20):2759-2763. PubMed ID: 28924126
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation.
    Sugata K; Yasunaga J; Kinosada H; Mitobe Y; Furuta R; Mahgoub M; Onishi C; Nakashima K; Ohshima K; Matsuoka M
    Cancer Res; 2016 Sep; 76(17):5068-79. PubMed ID: 27402079
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
    Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
    BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antibody therapy for Adult T-cell leukemia-lymphoma.
    Ishida T; Ueda R
    Int J Hematol; 2011 Nov; 94(5):443-52. PubMed ID: 21993874
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
    Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
    Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
    [No Abstract]   [Full Text] [Related]  

  • 78. CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
    Ito A; Sugita K; Adachi K; Hosoda Y; Motokura T; Yamamoto O
    Acta Derm Venereol; 2017 Mar; 97(3):377-378. PubMed ID: 27786349
    [No Abstract]   [Full Text] [Related]  

  • 79. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
    Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
    Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells.
    Shimauchi T; Imai S; Hino R; Tokura Y
    Clin Cancer Res; 2005 Mar; 11(6):2427-35. PubMed ID: 15788694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.